TRIM33 and cancer: New biomarkers, such as DM‐specific autoantibodies (anti‐Mi‐2, anti‐MDA5, anti‐TIF‐1γ, anti‐NXP2, and anti‐SAE) correlate with distinct clinical phenotypes with respect to organ involvement and malignancy in cancer‐associated myositis (CAM, (4)).